LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Suletud

Sektor Tervishoid

7.99 -1.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.98

Max

8.05

Põhinäitajad
By Trading Economics
Aktsiakasum	-0.172
Kasumimarginaal	-66.092
Töötajad	536

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+92.11 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	41M 990M
Eelmine avamishind	9.1
Eelmine sulgemishind	7.99

Uudiste sentiment

By Acuity

67%

33%

308 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

6.1 / 7.65 Toetus ja vastupanu

BioCryst Pharmaceuticals Inc Graafik

Seotud uudised

6. sept 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6. sept 2024, 21:18 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6. sept 2024, 21:05 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6. sept 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. sept 2024, 20:39 UTC

Tulu

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6. sept 2024, 20:35 UTC

Peamised uudised

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6. sept 2024, 20:34 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6. sept 2024, 20:11 UTC

Peamised uudised

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6. sept 2024, 19:51 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6. sept 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6. sept 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6. sept 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6. sept 2024, 18:27 UTC

Peamised uudised

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6. sept 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6. sept 2024, 18:15 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6. sept 2024, 18:12 UTC

Peamised uudised

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6. sept 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6. sept 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6. sept 2024, 17:30 UTC

Peamised uudised

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6. sept 2024, 17:27 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6. sept 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. sept 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6. sept 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6. sept 2024, 16:35 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6. sept 2024, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6. sept 2024, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

6. sept 2024, 16:20 UTC

Tulu

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6. sept 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. sept 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. sept 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

92.11% tõus

12 kuu keskmine prognoos

Keskmine 15.33 USD 92.11%

Kõrge 30 USD

Madal 7 USD

Põhineb 9 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi BioCryst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

6.1 / 7.65Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

308 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.